La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Aptorum Group Bilan de santé

Santé financière contrôle des critères 3/6

Aptorum Group possède un total de capitaux propres de $15.4M et une dette totale de $0.0, ce qui porte son ratio d'endettement à 0%. Son actif total et son passif total sont $20.6M et de $5.3M.

Informations clés

Ratio d'endettement

US$0

Dette

Ratio de couverture des intérêts	n/a
Argent liquide	US$2.01m
Fonds propres	US$15.38m
Total du passif	US$5.26m
Total des actifs	US$20.64m

Mises à jour récentes de la santé financière

Is Aptorum Group (NASDAQ:APM) In A Good Position To Deliver On Growth Plans?

Jul 14

Recent updates

We Think Shareholders Should Be Aware Of Some Factors Beyond Aptorum Group's (NASDAQ:APM) Profit

Apr 26

Do Institutions Own Aptorum Group Limited (NASDAQ:APM) Shares?

Jan 16

Aptorum files for early-stage trial for ALS-4 in Canada

Dec 21

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de APM ( $2.5M ) dépassent ses passifs à court terme ( $2.1M ).

Passif à long terme: Les actifs à court terme de APM ( $2.5M ) ne couvrent pas ses passifs à long terme ( $3.2M ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: APM est sans dette.

Réduire la dette: APM n'a aucune dette par rapport à il y a 5 ans, lorsque son ratio d'endettement était 30.9%.

Bilan

Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: APM dispose de moins d'un an de piste de trésorerie sur la base de son flux de trésorerie disponible actuel.

Prévisions de trésorerie: APM dispose de moins d'un an de marge de trésorerie si le flux de trésorerie disponible continue de croître à un taux historique de 3.6 % chaque année.

Aptorum Group Bilan de santé

Santé financière contrôle des critères 3/6

Informations clés

Mises à jour récentes de la santé financière

Aptorum Group Receives Nasdaq Approval to Transfer Listing to Nasdaq Capital Markets

Aptorum Group Limited Announces Voluntary Delisting from Euronext Paris

Aptorum Group Limited Receives Nasdaq Notification Letter Regarding Bid Price Deficiency

Is Aptorum Group (NASDAQ:APM) In A Good Position To Deliver On Growth Plans?

Recent updates

YOOV Group Holding Limited entered into an Agreement and Plan of Merger to acquire Aptorum Group Limited (NasdaqGM:APM) from Jurchen Investment Corporation and others for $250 million in a reverse merger transaction.

Aptorum Group Limited Announces Management Changes

Aptorum Group Limited, Annual General Meeting, Dec 20, 2023

Aptorum Group Limited announced that it has received $3 million in funding from Jurchen Investment Corporation

Aptorum Group Receives Nasdaq Approval to Transfer Listing to Nasdaq Capital Markets

Aptorum Group Limited Provides Updates on a Phase 1b/2a Clinical Trial for Repurposed Small Molecule Drug SACT-1 for Neuroblastoma

Aptorum Group Limited Announces Voluntary Delisting from Euronext Paris

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Aptorum Group Limited announced that it has received $3 million in funding from Aenco Technologies Ltd

Aptorum Group Limited announced that it expects to receive $3 million in funding

Aptorum Group Limited Receives Nasdaq Notification Letter Regarding Bid Price Deficiency

Price target decreased to US$11.50

Aptorum Group Limited, Annual General Meeting, Dec 21, 2022

Price target decreased to US$11.50

Aptorum Group GAAP EPS of -$0.05

First half 2022 earnings released: US$0.053 loss per share (vs US$0.47 loss in 1H 2021)

Aptorum Group Limited Launches NativusWell, a Novel Nutraceutical for Menopause, in Hong Kong

Is Aptorum Group (NASDAQ:APM) In A Good Position To Deliver On Growth Plans?

Aptorum Group Limited Announces Executive Changes

Consensus forecasts updated

Aptorum Group Limited Announces Executive Changes

Aptorum Group Limited Updates on Data from Completed Phase 1 Clinical Trial of SACT-1, Targeting Neuroblastoma

Full year 2021 earnings: Revenues exceed analyst expectations

US PTO Grants Patent to Aptorum Group Regarding RPIDD Infectious Disease Liquid Biopsy Technology DNA Library Preparation and Amplification Methods

Aptorum Group: Advancing Oncology, Autoimmune & Infectious Disease Therapies

Aptorum Group Announces Updates on the Clinical Validation of its RPIDD Infectious Disease Liquid Biopsy Technology

First half 2021 earnings released: US$0.47 loss per share (vs US$0.21 loss in 1H 2020)

Chief Operating Officer Siu-yan Ng has left the company

Aptorum Group Limited Announces Further Positive Interim Results of the Phase 1 Clinical Trial of ALS-4 Targeting Staphylococcus Aureus

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Aptorum Group Announces Positive Interim Phase I Clinical Trial Progress for ALS-4 Targeting Staphylococcus Aureus and Positive Pre-IND Progress for SACT-1 Targeting Neuroblastoma

Aptorum inks development agreement with Exeltis

We Think Shareholders Should Be Aware Of Some Factors Beyond Aptorum Group's (NASDAQ:APM) Profit

Full year 2020 earnings released: EPS US$0.20 (vs US$0.64 loss in FY 2019)

New 90-day high: US$4.17

Do Institutions Own Aptorum Group Limited (NASDAQ:APM) Shares?

New 90-day high: US$3.31

Aptorum files for early-stage trial for ALS-4 in Canada

New 90-day low: US$1.22

New 90-day low - US$1.55

First half earnings released

New 90-day low - US$2.84

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Analyse des pistes de trésorerie

Découvrir des entreprises saines